The Application of the Therapeutic Drug Monitoring (TDM) of First and Second-Line Drugs for Multidrug-Resistant Tuberculosis Patients (MDRTB)

Authors

  • Anun Chaikoolvatana College of Medicine and Public Health, Ubon Ratchathani University, Ubon Ratchathani 34190
  • Yun-Bae-Kim Kim Chungbuk National University
  • Cholada Chaikoolvatana Faculty of Nursing, Phayao University, Phayao 56000
  • Nawaporn Saisingha Rajamangala University of Technology, Surin Campus, Surin 32000
  • Plakorn Suebsamran College of Medicine and Public Health, Ubon Ratchathani University, Ubon Ratchathani 34190

Keywords:

Pyrazinamide (PZA), cycloserine multidrug resistant tuberculosis, therapeutic drug monitoring (TDM)

Abstract

Objective:  The study aimed to evaluate the effectiveness, safety, and drug compliance among MDRTB-patients who either undergo therapeutic drug monitoring (TDM) or not to assess the full benefit of TDM related to the disease treatment.
Methods: It was a quasi-experimental design. The study group underwent TDM process to measure serum drug concentrations of pyrazinamide (PZA) and cycloserine (CS), whereas the control group went through the regular process of treatment without taking TDM.  All patient information and lab tests were investigated.  Descriptive statistics including, frequency, percentage, mean, SD, percentage (s) as well as analytical statistics at confidence interval of 95% (p<0.05) including Fisher’s Exact test were used. 
Results: There were no significant differences between measuring and calculating PZA concentrations throughout 4-month periods (p>.05).  Overall, the treatment success of MDR-TB among the subjects in both groups were still not satisfied.  The common side effects of both medications were reported.  Serum concentrations of PZA and cylcoserine were not significantly related to the side effects.  Similarly, there was no significant relation between serum concentrations of PZA and drug compliance.
Conclusion: TDM is described as an investigational tool to explore means of improving therapeutic outcomes and reducing toxicity of the current MDRTB medications.  Further investigations are still needed.

Downloads

Published

24-03-2017

How to Cite

Chaikoolvatana, A., Kim, Y.-B.-K., Chaikoolvatana, C., Saisingha, N., & Suebsamran, P. (2017). The Application of the Therapeutic Drug Monitoring (TDM) of First and Second-Line Drugs for Multidrug-Resistant Tuberculosis Patients (MDRTB). Siriraj Medical Journal, 69(2), 85–93. Retrieved from https://he02.tci-thaijo.org/index.php/sirirajmedj/article/view/80897

Issue

Vol. 69 No. 2 (2017): March-April

Section

Original Article

License

Users are free to share, copy, and redistribute all articles published in the Siriraj Medical Journal (SMJ) in any medium or format as long as you follow the following terms:

  • Attribution — You must give appropriate credit, provide a link to the material, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the publisher endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes.
  • NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.